Hypoparathyroidism Market Report 2026

The hypoparathyroidism market size has grown strongly in recent years. It will grow from $1.03 billion in 2025 to $1.12 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to thyroid surgery complications, calcium deficiency cases, rare disease awareness, hospital endocrine care, hormone replacement availability.

The hypoparathyroidism market size is expected to see strong growth in the next few years. It will grow to $1.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to advancements in recombinant therapies, improved rare disease diagnosis, patient adherence programs, specialty clinic expansion, precision endocrinology adoption. Major trends in the forecast period include increased diagnosis of rare endocrine disorders, growing use of recombinant parathyroid hormones, expansion of long-term calcium management therapies, improved awareness of post-surgical complications, development of adjunctive supportive treatments.

The rising incidence of thyroid cancer is expected to drive the growth of the hypoparathyroidism market in the coming years. Thyroid cancer is a type of cancer in which abnormal cells develop in the thyroid gland, often forming a lump in the neck. The increase in thyroid cancer cases is largely due to advancements in diagnostic imaging technologies, which allow for earlier and more frequent detection of small, asymptomatic thyroid nodules. Thyroid cancer can accelerate hypoparathyroidism by increasing the number of thyroid surgeries, which may inadvertently damage the parathyroid glands. This can result in calcium imbalances and chronic hormone deficiencies, creating demand for long-term disease management solutions. For example, according to the American Cancer Society in May 2024, the number of new thyroid cancer cases reached 44,020 in 2025, up from 43,720 in 2023. As a result, the increasing incidence of thyroid cancer is driving growth in the hypoparathyroidism market.

Leading companies in the hypoparathyroidism market are focusing on developing advanced products, such as those based on TransCon technology, to improve treatment efficacy and patient outcomes. TransCon (Transient Conjugation) technology is a proprietary platform designed to optimize drug delivery. For instance, in January 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched YORVIPATH (palopegteriparatide) in Germany and Austria for the treatment of adults with chronic hypoparathyroidism. YORVIPATH, a once-daily prodrug of parathyroid hormone (PTH 1-34), is designed to maintain physiological PTH levels over 24 hours, addressing the underlying hormone deficiency in chronic hypoparathyroidism.

In July 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Amolyt Pharma SAS for an undisclosed amount. This acquisition aims to strengthen AstraZeneca’s rare disease portfolio, particularly in endocrine disorders, by leveraging Amolyt Pharma’s innovative pipeline and clinical-stage therapies. Amolyt Pharma SAS, a France-based biotechnology company, is developing eneboparatide, a long-acting parathyroid hormone analog for the treatment of hypoparathyroidism.

Major companies operating in the hypoparathyroidism market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., BridgeBio Pharma Inc., Ascendis Pharma A/S, Extend Biosciences Inc., Entera Bio Ltd.

North America was the largest region in the hypoparathyroidism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypoparathyroidism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypoparathyroidism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the hypoparathyroidism market by raising the price of recombinant parathyroid hormone, calcium supplements, and injectable therapies. Hormone replacement therapy and adjunctive therapy segments are most affected, especially in North America and Europe. Hospital pharmacies and specialty clinics face cost increases. However, tariffs are supporting domestic production of endocrine drugs and biologics.

The hypoparathyroidism market research report is one of a series of new reports that provides hypoparathyroidism market statistics, including hypoparathyroidism industry global market size, regional shares, competitors with a hypoparathyroidism market share, detailed hypoparathyroidism market segments, market trends and opportunities, and any further data you may need to thrive in the hypoparathyroidism industry. This hypoparathyroidism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hypoparathyroidism is an uncommon endocrine disorder in which the parathyroid glands produce inadequate amounts of parathyroid hormone (PTH), resulting in low calcium and elevated phosphorus levels in the blood. Parathyroid hormone (PTH) primarily functions to regulate and maintain stable calcium and phosphorus levels, which are vital for proper nerve, muscle, and bone activity. This condition can arise due to surgical removal or injury to the parathyroid glands, autoimmune disorders, genetic factors, or, in rare cases, unknown (idiopathic) causes.

Treatment for hypoparathyroidism mainly involves hormone replacement therapy and supportive therapies. Hormone replacement therapy (HRT) involves administering hormones to replace or supplement those that the body is not producing adequately. Treatments include hormone replacement therapy itself, calcium and vitamin D supplements, and new emerging therapies. These therapies can be administered orally or parenterally and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, catering to end users such as hospitals, specialty clinics, and homecare settings.

The hypoparathyroidism market consists of revenues earned by entities by providing services such as diagnostic testing, patient monitoring, telemedicine consultations, and specialized care for chronic disease management and education. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoparathyroidism market also includes sales of phosphate binders, and medical devices or diagnostic kits used for monitoring calcium, phosphorus, and parathyroid Hormone levels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.